Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, August 1st, 2024
1:05 PM - 4:45 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Bridget Bradley, PharmD; Douglas Carr, MD; Tim Langford, PharmD; Eriko Onishi, MD; Eddie Saito, PharmD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Dee Weston, JD; Trevor Douglass, DC; Jennifer Bowen; Kyle Hamilton, Michael Yu;

Audience: Steve Hall, Genentech; Jason Linde, FARE; Tracy Lehto, parent; William Lam, Madrigal; Kat Khachatourian, Novo Nordisk; Tyler Lincoln, Arcutis Biotherapeutics; Rochele Yang, Teva; Melinda Turkington, UCB; Erin Nowak, AbbVie; Josh Akers, Eli Lilly; Kim Eggert; Greg Mills, Capital Results; Tina Hartmann, Arcutis; Brent Fushimi; Matt Prokop, America Diabetes Association; Melissa Snider, Gilead; Melissa Bailey Hall, LillyUSA; Jill Caroll, Karuna; Donesha Belin, UHA; Mark Kantor, AllCare Health; Seth Fritts, Acadia; Matt Worthy, OHSU; Jenny Todenhagen, Genentech; Gina Heinen, Novo Nordisk; Denzell Sabado, Genentech; Alexandria Harrold, UCB; Chris Ferrin, IHN; Sean Staff, Acadia; Leanne Yantis, AllCare; Lindsey Walter, Novartis; Elva Van Devender, Umpqua Health; Lynda Finch, Biogen; Aihan Le, Moda/EOCCO; Ryan Tran, Moda/EOCCO; JJ Roth, Mirum Pharma; Ken Liu, Madrigal; Daria Meleshkina, Moda/EOCCO; Jeff White, Sumitomo Pharma; Tam Dang-Tan, Novo Nordisk; Karen Wilund; Sheila Albeke, IHN-

CCO; Susan Manns, Cullari Communication Global; Samyukta Vendrathi; Jayme Sweeny; Leif Bruce, Novo Nordisk; Lisa Pulver; Leannne Yantis, AllCare; Matt Worthy, OHSU; Katie Scheeler, EOCCO/Moda; Tina Shriner; Raya Nematian

(*) Provided verbal testimony

OREGON HEALTH AUTHORITY

OSU Oregon State University College of Pharmacy

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

I. CALL TO ORDER

A. Roll Call & Introductions
- Called to order at approx. 1:05 p.m., introductions by Committee and staff

B. Conflict of Interest Declaration – no new conflicts of interest were declared

C. Approval of Agenda and June 2024 Minutes presented by Roger Citron, RPh
ACTION: Motion to approve, 2nd, all in favor

D. Department Update provided by Andrew Gibler, PharmD

E. Mental Health Clinical Advisory Group Update provided by Andrew Gibler, PharmD

II. CONSENT AGENDA TOPICS

A. Quarterly Utilization Report

B. Zelsuvmi™ (berdazimer) Abbreviated Drug Review-
Recommendation:
-Apply the Drugs for Non-funded Conditions prior authorization (PA) criteria to limit use to funded conditions

C. Oncology Prior Authorization (PA) Updates
Recommendation:
- Add: Anktiva® (nogapendekin alfa inbakicept-pmln); Imdelltra™ (tarlatamab-dlle); and Ojemda™ (tovorafenib) to Table 1 in the Oncology Agents PA criteria

D. Orphan Drug Policy Updates
Recommendation:
- Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of: Voydeya™ (danicopan); Fabhalta® (iptacopan); Xolremdi™ (mavorixafor); Rystiggo® (rozanolixizumabnoli); Qalsody® (tofersen); and Zilbrysq® (zilucoplan) based on FDA-approved labeling

ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. ProDUR Report: Lan Starkweather, PharmD

B. RetroDUR Report: Dave Engen, PharmD

C. Oregon State Drug Review: Kathy Sentena, PharmD
1. **Hepatitis C Care for Primary Care Providers**
2. **Asthma Relief Inhaler Drug Use Evaluation**

OREGON HEALTH AUTHORITY

OSU Oregon State University College of Pharmacy

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

IV. DUR NEW BUSINESS

A. Xolair® (omalizumab) PA Update: Deanna Moretz, PharmD
Recommendation:
- Update PA criteria for Targeted Immune Modulators (TIMs) for Severe Asthma and Atopic Dermatitis to include omalizumab for food allergies in patients at high risk of frequent and/or severe allergic reactions due to accidental exposure to foods
- Remove diagnostic requirement for a food challenge from the Xolair and Palforzia PA criteria

Public Comment: Steve Hall, Genentech; Jason Linde, FARE; Tracy Lehto, parent
ACTION: The Committee recommended amending PA to permit use of in vitro reactivity to a perennial allergen as an option for diagnostic allergy testing
Motion to approve, 2nd, all in favor

B. Non-alcoholic Steatohepatitis (NASH) and Weight Management Drugs for NASH and Cardiovascular Disease: Sara Fletcher, PharmD; Sarah Servid, PharmD
Recommendation:
- Implement PA for resmetirom to ensure appropriate use
- Cover specific GLP-1 RAs with compendia-support for treatment of NASH in adult patients with overweight or obesity
- Update Weight Management & GLP-1 PA criteria as proposed
- Remove age restrictions for semaglutide in people with established CV disease with overweight or obesity because this population is at increased risk of recurrent MACE independent of age

Public Comment: William Lam, Madrigal; Kat Khachatourian, Novo Nordisk
ACTION: The Committee recommended - in the absence of a liver biopsy - include questions to confirm other causes of liver disease have been ruled-out (esp. alcoholic liver disease) and confirm that the patient has 3 of 5 risk factors/comorbidities for NASH
- Add coverage of GLP-1 RAs for only F2 to F3 fibrosis stage
- For diagnosis of NASH, require biopsy OR presence of 3 comorbidities with other causes of liver disease ruled out).
- Require prescribing by or in consultation with a specialist for off-label use for NASH

Motion to approve, 2nd, all in favor

V. PREFERRED DRUG LIST (PDL) NEW BUSINESS

A. Antacids Class Update and New Drug Evaluation
ACTION: Deferred to future meeting

OREGON HEALTH AUTHORITY
OSU Oregon State University College of Pharmacy
Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

B. Targeted Immune Modulators DERP Summary: Deanna Moretz, PharmD
Recommendations:
- Update TIMs PA criteria as proposed to include coverage for new drugs and indications and tiered step therapy for common diagnoses
-Maintain etrasimod, mirikizumab, bimekizumab, deucravacitinib, and spesolimab as non-preferred on the PDL
- Evaluate costs in executive session
Public Comment: Tyler Lincoln, Arcutis Biotherapeutics**;** Rochele Yang, Teva; Melinda Turkington, UCB; Erin Nowak, AbbVie; Josh Akers, Eli Lilly
ACTION: The Committee recommended that currently preferred products Humira and Enbrel be designated Tier 1
Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Bridget Bradley, PharmD; Douglas Carr, MD; Tim Langford, PharmD; Eriko Onishi, MD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton

VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Targeted Immune Modulators
Recommendation:
- Make Avsola (infliximab-axxq), Simlandi (brand name only), Amjevita 100 mg/mL (high-concentration), and generic adalimumab-fkjp 50 mg/mL (low-concentration) preferred and Tier 1
- Make Taltz (ixekizumab), Otezla (apremilast), and Xeljanz (tofacitinib citrate) preferred and Tier 2
- Make Cosentyx (secukinumab) non-preferred
ACTION: Motion to approve, 2nd, all in favor

VIII. ADJOURN